David A. Zilberberg
Lawyers

Filters
American Commercial Lines prepackaged chapter 11 restructuring and DIP financing
Davis Polk is advising an ad hoc group (the “Ad Hoc Group”) of prepetition secured term lenders and postpetition DIP term lenders in connection with American Commercial Lines Inc.’s …
Davis Polk Advises Universal Scientific Industrial on Its Acquisition of Asteelflash
Davis Polk is advising Universal Scientific Industrial (Shanghai) Co., Ltd. on its acquisition of Asteelflash. Under the terms of the transaction agreement, USI will acquire 100% of the…
Plug Power Inc. $127 Million Common Stock Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 46,000,000 shares of common stock of Plug Power Inc. for…
Las Vegas Sands Corp. $500 Million Notes Offering
Davis Polk advised the underwriters in connection with the SEC-registered notes offering by Las Vegas Sands Corp. of $500 million of its 2.900% senior notes due 2025. Las Vegas Sands…
AbbVie Inc. $30 Billion Senior Notes Offering
Davis Polk advised the initial purchasers in connection with an unregistered offering by AbbVie Inc. of $30 billion aggregate principal amount of senior notes, consisting of (i) $750…
Otter Tail Corporation $75 Million SEC-Registered At-The-Market Offering
Davis Polk advised the distribution agent on an SEC-registered at-the-market offering by Otter Tail Corporation of its common shares for up to an aggregate amount of $75 million.
…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…
Black Hills $700 Million Senior Notes Offering
Davis Polk advised the representatives and joint book-running managers of an SEC-registered offering by Black Hills Corporation of $400 million aggregate principal amount of its 3.050%…
BioXcel Therapeutics, Inc. $18.9 Million Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303,030 shares of its common stock. The common stock is listed on the…
McKesson Corporation $4 Billion Revolving Credit Agreement
Davis Polk advised the joint lead arranger and bookrunner, and the administrative agent, in connection with a $4 billion unsecured revolving credit facility provided to McKesson Corporation…